Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Anaplastic Large Cell Lymphoma”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)WithdrawnNCT03719898
What this trial is testing

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
Fox Chase Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00939770
What this trial is testing

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Who this might be right for
Recurrent Childhood Anaplastic Large Cell LymphomaRecurrent Malignant Solid NeoplasmRecurrent Neuroblastoma+3 more
Children's Oncology Group 122
Early research (Phase 1)UnknownNCT04480788
What this trial is testing

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Who this might be right for
T Lymphoblastic Leukemia/LymphomaExtramedullary NK-T-cell Lymphoma, Nasal TypePeripheral T-cell Lymphoma, Nonspecific+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 9
Large-scale testing (Phase 3)Study completedNCT02737501
What this trial is testing

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals 275
Testing effectiveness (Phase 2)WithdrawnNCT02729961
What this trial is testing

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveCD30-Positive Neoplastic Cells PresentSystemic Anaplastic Large Cell Lymphoma
University of Washington
Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Not applicableUnknownNCT05934045
What this trial is testing

Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

Who this might be right for
ALK-Positive Anaplastic Large Cell Lymphoma
University Hospital, Toulouse 80
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Study completedNCT02561273
What this trial is testing

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveHepatosplenic T-Cell Lymphoma+7 more
University of Nebraska 54
Not applicableStudy completedNCT01366170
What this trial is testing

Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma
Children's Oncology Group 7
Post-approval studies (Phase 4)WithdrawnNCT02487316
What this trial is testing

Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Who this might be right for
Systemic Anaplastic Large-Cell Lymphoma
Jun Zhu
Testing effectiveness (Phase 2)Study completedNCT01524926
What this trial is testing

CREATE: Cross-tumoral Phase 2 With Crizotinib

Who this might be right for
Locally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1+3 more
European Organisation for Research and Treatment of Cancer - EORTC 582
Early research (Phase 1)Looking for participantsNCT07001384
What this trial is testing

Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Who this might be right for
Anaplastic Lymphoma KinaseAnaplastic Large Cell Lymphoma
Memorial Sloan Kettering Cancer Center 30
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT03075553
What this trial is testing

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 Infection+14 more
Mayo Clinic 12
Testing effectiveness (Phase 2)Study completedNCT01198665
What this trial is testing

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T Cell Lymphoma UnspecifiedAnaplastic Large Cell Lymphoma, ALK-negativeAngioimmunoblastic T Cell Lymphoma+1 more
Samsung Medical Center 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625
What this trial is testing

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more
National Cancer Institute (NCI) 68
Not applicableLooking for participantsNCT05978141
What this trial is testing

A Registry for People With T-cell Lymphoma

Who this might be right for
T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+28 more
Memorial Sloan Kettering Cancer Center 1,000
Testing effectiveness (Phase 2)Ended earlyNCT04676360
What this trial is testing

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Who this might be right for
Relapsed Plasmablastic LymphomaRefractory Plasmablastic LymphomaAnaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Jacob Soumerai, MD 10
Next Page